Dolutegravir Sodium
Brand name: Tivicay
Rank #76 of 500 drugs by total cost
$251.7M
Total Cost
102,995
Total Claims
$251.7M
Total Cost
2,253
Prescribers
$2,444
Cost per Claim
6,687
Beneficiaries
106,915
30-Day Fills
$112K
Avg Cost/Provider
46
Avg Claims/Provider
About Dolutegravir Sodium
Dolutegravir Sodium (sold as Tivicay) was prescribed 102,995 times by 2,253 Medicare Part D providers in 2023, costing the program $251.7M. At $2,444 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 73 | Venetoclax (Venclexta) | $259.6M | 28,191 |
| 74 | Zanubrutinib (Brukinsa) | $256.8M | 19,239 |
| 75 | Metoprolol Succinate (Metoprolol Succinate) | $256.3M | 12,847,535 |
| 76 | Dolutegravir Sodium (Tivicay) | $251.7M | 102,995 |
| 77 | Abemaciclib (Verzenio) | $242.2M | 16,125 |
| 78 | Abacavir/Dolutegravir/Lamivudi (Triumeq) | $238.1M | 61,147 |
| 79 | Riociguat (Adempas) | $236.6M | 17,620 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology